Navigation Links
University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
Date:7/7/2008

WHITE PLAINS, N.Y., July 7 /PRNewswire/ -- The Leukemia & Lymphoma Society has awarded a $550,000 grant to Jonathan Friedberg M.D., M.M.Sc., of the James P. Wilmot Cancer Center at the University of Rochester Medical Center. Millennium Pharmaceuticals, The Takeda Oncology Company, of Cambridge, Mass., is funding the first two years of the five-year program.

The Scholar in Clinical Research Career Development Grant will support Dr. Friedberg's work on a new targeted treatment for lymphoma patients.

Dr. Friedberg is studying the drug R788 for patients with indolent and mantle cell non-Hodgkin lymphoma (NHL). This drug inhibits the molecule called SYK, which controls the survival of B-cells in lymphoma patients. Dr. Friedberg has already shown in several patients that R788 is safe and effective. He is now using mouse models to evaluate R788 in combination with other agents to kill lymphoma cells even better. Once the most promising combination is identified, Dr. Friedberg will pursue a clinical trial enrolling patients with relapsed indolent and mantle cell NHL.

"To effectively eradicate cancers we must learn which molecules cause them and then develop new treatments that kill cancer cells without harming healthy cells," said Barton Kamen, M.D., PhD, Chief Medical Officer of LLS. "Dr. Friedberg's work shows exceptional promise and is likely to lead to improved treatments for patients with various types of lymphoma."

Friedberg is Associate Professor of Medicine, and Director of Hematological Malignancies Clinical Research at the Wilmot Cancer Center. He is leading a number of clinical studies of new agents for lymphoma patients.

The LLS Career Development Program funds talented investigators at different points in their developing careers: Fellows and Special Fellows during their post-doctoral training years, and Scholars and Scholars in Clinical Research early in their independent academic positions. The program thereby recruits and supports young scientists in blood cancer research, helping to populate the field with the best and brightest young researchers who are accomplishing cutting-edge research in established and new laboratories.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 67 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $600 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the LLS Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif

914.821.8958

andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
2. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
3. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
4. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
5. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
6. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
7. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
8. BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University
9. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
10. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
11. Wayne State University and Oakwood Partner in New Device to Combat Congestive Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
(Date:2/27/2017)... -- Now in its seventh year, the Pharmaceutical ... successful at developing and commercialising innovation. ... The Index can be summarised ... two different companies in early phase, which would make the ... of each company,s performance between 2011 and 2016, the 2017 ranking sees ...
(Date:2/27/2017)... , February 27, 2017 Leading Countries, ... market is expected to grow at a CAGR of 8.9% ... expected to grow at a CAGR of 9.1% from 2016 to ... in 2027. ... this report will benefit you Read on to discover how ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... This is ... the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 ... 17025:2005 is the globally recognised standard that sets out requirements for the technical ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... in North America, today announced it would be offering some it’s exclusive product ... itself on crafting quality and unique baby clothing/feeding products, will team up with ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... and reporting for healthcare organizations. This comprehensive and customizable solution empowers StaffBridge ... StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical reporting data, ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports ... a study released today at the 1st Pan American Parkinson’s and Movement Disorders ... be effective in improving cognitive function in PD patients. This study, led by ...
(Date:2/25/2017)... ... , ... FCPX users now have the ability to sharpen a desired color ... users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical sharpening, ... users can visually see the color range effected with ease all within Final ...
Breaking Medicine News(10 mins):